Effect of a low dose combined oral contraceptive pill on the hormonal profile and cycle outcome following COS with a GnRH antagonist protocol in women over 35 years old

Abstract

This prospective study examines if pre-treatment with two different doses of an oral contraceptive pill (OCP) modifies significantly the hormonal profile and/or the IVF/ICSI outcome following COS with a GnRH antagonist protocol. Infertile patients were allocated to receive either OCP containing 0.03 mg of ethinylestradiol and 3 mg of drospirenone, or OCP containing 0.02 mg of ethinylestradiol and 3 mg of drospirenone prior to initiation of controlled ovarian stimulation (COS) with recombinant gonadotropins on a variable multi-dose antagonist protocol (Ganirelix), while the control group underwent COS without OCP pretreatment. Lower dose OCP was associated with recovery of FSH on day 3 instead of day 5, but the synchronization of the follicular cohort, the number of retrieved oocytes and the clinical pregnancy rate were similar to higher dose OCP.

Chinese abstract

这个前瞻性的研究是为了检测联合用GnRHa超促排卵方案治疗前用2种不同剂量的口服避孕药是否可以明显改善激素水平和/或IVF/ICSI的结果。不孕患者被分为接受口服避孕药含EE 0.03mg和屈螺酮3mg，或者口服避孕药含EE 0.02mg和屈螺酮3mg，在多剂量变化的GnRHa加重组促性腺激素超促排卵（(Ganirelix)）启动前开始应用，而对照组只用超促排卵治疗不用口服避孕药。低剂量口服避孕药在第3天而不是第5天与FSH的恢复相关，但卵泡同步化及卵母细胞回收及妊娠率方面与口服避孕药较高剂量组相似。

• Contraceptive pill
• COS
• ganirelix
• GnRH antagonist
• ICSI
• IVF
• ovarian stimulation